The stock has a 36-month beta value of 0.89. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATHE is 8.32M, and at present, short sellers hold a 1.09% of that float. On April 30, 2024, the average trading volume of ATHE was 86.54K shares.
ATHE) stock’s latest price update
Alterity Therapeutics Ltd ADR (NASDAQ: ATHE) has experienced a decline in its stock price by -12.55 compared to its previous closing price of 2.51. However, the company has seen a gain of 3.05% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-10 that MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.
ATHE’s Market Performance
ATHE’s stock has risen by 3.05% in the past week, with a monthly rise of 6.04% and a quarterly rise of 10.30%. The volatility ratio for the week is 16.56% while the volatility levels for the last 30 days are 14.31% for Alterity Therapeutics Ltd ADR The simple moving average for the past 20 days is 2.25% for ATHE’s stock, with a -7.48% simple moving average for the past 200 days.
ATHE Trading at 12.37% from the 50-Day Moving Average
After a stumble in the market that brought ATHE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.43% of loss for the given period.
Volatility was left at 14.31%, however, over the last 30 days, the volatility rate increased by 16.56%, as shares surge +12.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.61% upper at present.
During the last 5 trading sessions, ATHE rose by +3.05%, which changed the moving average for the period of 200-days by -19.49% in comparison to the 20-day moving average, which settled at $2.16. In addition, Alterity Therapeutics Ltd ADR saw -11.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ATHE
Current profitability levels for the company are sitting at:
- -3.52 for the present operating margin
- 0.93 for the gross margin
The net margin for Alterity Therapeutics Ltd ADR stands at -3.37. The total capital return value is set at -0.12. Equity return is now at value -52.42, with -43.13 for asset returns.
Based on Alterity Therapeutics Ltd ADR (ATHE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -68.52.
Currently, EBITDA for the company is -15.19 million with net debt to EBITDA at 5.46. When we switch over and look at the enterprise to sales, we see a ratio of 18.23. The receivables turnover for the company is 0.09for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To sum up, Alterity Therapeutics Ltd ADR (ATHE) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
